Clinical Study
In Crohn's Disease, Anti-TNF- Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells
Table 1
Patient characteristics.
| | |
| Gender: female/male | 6/7 (46/54%) | Disease type | | Inflammatory | 6 (46%) | Stricturing | 4 (31%) | Inflammatory + perianal | 3 (23%) | Disease location | | Ileum | 2 (15%) | Colon | 3 (23%) | Ileocolon | 8 (62%) | Medication (at first endoscopy) | | Azathioprine or 6- | 9 (69%) | mercaptopurin | 2 (15%) | Methotrexate | 9 (69%) | Corticosteroids | 9 (69%) | Mesalamine | 2 (15%) | Salazosulphapyridine | 1 (8%) | Metronidazole | | Medication (at second endoscopy) | | Azathioprine or 6- | 11 (85%) | mercaptopurin | 2 (15%) | Methotrexate | 0 (0%) | Corticosteroids | 8 (62%) | Mesalamine | 2 (15%) | Salazosulphapyridine | 0 (0%) | Metronidazole | | Previous anti-TNF- | 4 (31%) | treatment | |
| | Median (range) |
| Age, years, | 23 (19–44) | Disease duration, years | 5.1 (0.4–27.0) | CDEIS | | Before treatment | 14.4 (1.8–25.3) | After treatment | 4.4 (0.0–11.2), | CDAI | | Before treatment | 174 (50–605) | After treatment | 64 (24–112), | Fecal calprotectin g/g | | Before treatment | 1173 (88–15326) | After treatment | 127 (13–1419), | Serum CRP | | Before treatment | 8 (<5–42) | After treatment | <5 (<5-6), |
|
|
CDAI: Crohn’s disease activity index; CDEIS: Crohn’s disease index of severity.
|